Morphic Holding (Morphic Holding) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Debt-to-Equity?

Morphic Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.81 Mil. Morphic Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.47 Mil. Morphic Holding's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $663.58 Mil. Morphic Holding's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Morphic Holding's Debt-to-Equity or its related term are showing as below:

MORF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.01 Max: 0.02
Current: 0.01

During the past 7 years, the highest Debt-to-Equity Ratio of Morphic Holding was 0.02. The lowest was -0.02. And the median was 0.01.

MORF's Debt-to-Equity is ranked better than
99.91% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs MORF: 0.01

Morphic Holding Debt-to-Equity Historical Data

The historical data trend for Morphic Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Debt-to-Equity Chart

Morphic Holding Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

Morphic Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	-	-	0.01

Competitive Comparison of Morphic Holding's Debt-to-Equity

For the Biotechnology subindustry, Morphic Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Morphic Holding's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Debt-to-Equity falls into.

Morphic Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Morphic Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.628	+	0.716)	/	697.022
	=	0.00

Morphic Holding's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.807	+	1.474)	/	663.58
	=	0.00

Morphic Holding (NAS:MORF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Morphic Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Morphic Holding (Morphic Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

31Y:Germany 31Y:Germany

Address

35 Gatehouse Drive, A2, Waltham, MA, USA, 02451

Website

http://www.morphictx.com

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Executives

William Devaul	officer: General Counsel and Secretary	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers	officer: Chief Scientific Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin	officer: CFO and COO	ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni	director, officer: President and CEO	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr	officer: VP Finance and Ops, Secretary	CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery	director	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer	director, 10 percent owner	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde	officer: Chief Medical Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda	director	281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal	director	C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199